>>3 Dividend Stocks for a Richer Retirement<< (sponsored)
The Online Investor



BLTE Stock: Belite Bio Inc

This BLTE stock page provides quote data, company profile information, price chart, news, related articles, short interest, analyst target links, and other research tools for Belite Bio Inc.

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. Co. is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, LBS-008 as an oral daily treatment for STGD1 and Geographic Atrophy patients.

BLTE — Key Stats (updated 19 minutes ago)
Company Name:  Belite Bio Inc
Short interest:  BLTE short interest
Sector:  Biotechnology
Number of ETFs Holding BLTE:  8
BLTE — News
BLTE — Price Chart

BLTE Stock Page: Belite Bio Inc Quote, Chart, News, and Research | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2026, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.